Downregulation of fibulin-3 gene by promoter methylation in colorectal cancer predicts adverse prognosis

Neoplasma

Volumn 58, Issue 5, 2011, Pages 441-448

  Tong, J D ^a   Jiao, N L ^b   Wang, Y X ^a   Zhang, Y W ^a   Han, F ^a  

^a YANGZHOU UNIVERSITY   (China)

^b WANNAN MEDICAL COLLEGE   (China)

Author keywords

CRC; Fibulin 3; Immunohistochemistry; Methylation; Prognosis

Indexed keywords

FIBULIN; FIBULIN 3; GENOMIC DNA; UNCLASSIFIED DRUG; EFEMP1 PROTEIN, HUMAN; SCLEROPROTEIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA EXTRACTION; DNA METHYLATION; FEMALE; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MICRODISSECTION; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ADENOMA; AGED; CANCER STAGING; COLORECTAL TUMOR; DOWN REGULATION; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROMOTER REGION; SURVIVAL RATE;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA METHYLATION; DOWN-REGULATION; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL RATE;

EID: 80052889950     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_05_441     Document Type: Article

References (31)

1. PARKIN DM, BRAY F, FERLAY J, PISAMI P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. doi:10.3322/canjclin.55.2.74
2. SAIF MW, CHU E: Biology of colorectal cancer. Cancer J 2010; 16: 196-201. doi:10.1097/PPO.0b013e3181e076af
3. TIMPL R, SASAKI T, KOSTKA G, CHU ML: Fibulins: a versatile family of extracellular matrix proteins. Nat Rev Mol Cell Biol 2003; 4: 479-489. doi:10.1038/nrm1130
4. KOBAYASHI N, KOSTKA G, GARBE JH, KEENE DR, BACHINGER HP et al.: A comparative analysis of the fibulin protein family.Biochemical characterization, binding interactions, and tissue localization. J Biol Chem 2007; 282: 11805-11816. doi:10.1074/jbc.M611029200
5. DE VEGA S, IWAMOTO T, YAMASDA Y: Fibulins: multiple roles in matrix structures and tissue functions. Cell Mol Life Sci 2009; 66: 1890-1902. doi:10.1007/s00018-009-8632-6
6. PUPA SM, GIUFFRE S, CASTIGLIONI F, BERTOLA L, CANTU M et al.: Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res 2007; 67: 4271-4277. doi:10.1158/0008-5472.CAN-06-4162
7. YI CH, SMITH DJ, WEST WW, HOLLINGSWORTH MA: Loss of fibulin-2 expression is associated with breast cancer progression. Am J Pathol 2007; 170: 1535-1545. doi:10.2353/ ajpath.2007.060478
8. ALBIG AR, SCHIEMANN WP: Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA Cell Biol 2004; 23: 367-379. doi:10.1089/104454904323145254
9. ALBIG AR, NEIL JR, SCHIEMANN WP: Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res 2006; 66: 2621-2629. doi:10.1158/0008-5472.CAN-04-4096
10. SADR-NABAVI A, RAMSTER J, VOLKMANN J, NAEHRIG J, WIESMANN F et al.: Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer 2009; 124: 1727-1735. doi:10.1002/ijc.24108
11. YUE W, DACIC S, SUN Q, LAN DRENEAU R, GUO M et al.: Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation. Clin Cancer Res 2007; 13: 4336-4344. doi:10.1158/1078-0432.CCR-07-0015
12. WANG R, ZHANG YW, CHEN LB: Aberrant promoter methylation of FBLN-3 gene and clinicopathological significance in non-small cell lung carcinoma. Lung Cancer 2010; 69: 239-244. doi:10.1016/j.lungcan.2009.10.009
13. NOMOTO S, KANDA M, OKAMURA Y, NICHIKAWA Y, QIYONG L et al.: Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis. Ann Surg Oncol 2010; 17: 923-932. doi:10.1245/s10434-009-0790-0
14. SEELIGER H, CAMAJ P, ISCHENKO I, KLEESPIES A, DE TONI EN et al.: EFEMP1 expression promotes in vivo tumor. growth in human pancreatic adenocarcinoma. Mol Cancer. Res 2009; 7: 189-198. doi:10.1158/1541-7786.MCR-08-0132
15. HU B, THITRTAMARA-RAJAMANI KK, SIM H, VIAPIANO MS: Fibulin-3 is uniquely upregulated in malignant gliomas and promotes tumor cell motility and invasion. Mol Cancer Res 2009; 7: 1756-1770. doi:10.1158/1541-7786. MCR-09-0207
16. EN-LIN S, SHENG-GUO C, HUA-QIAO W: The expression of EFEMP1 in cervical carcinoma and its relationship with prognosis. Gynecol Oncol 2010; 117: 417-422. doi:10.1016/ j.ygyno.2009.12.016
17. DONG Y, WANG J, SHENG Z, LI G, MA H et al.: Down-regulation of EphA1 in colorectal carcinomas correlates with invasion and metastasis. Mod Pathol 2009; 22: 151-160. doi:10.1038/modpathol.2008.188
18. SIRIVATANAUKSORN Y, SIRIVATANAUKSORN V, BHATTACHARYA S, DAVIDSON BR, DHILLON AP et al.: Evolution of genetic abnormalities in hepatocellular carcinomas demonstrated by DNA fingerprinting. J Pathol 1999; 189:344-350. doi:10.1002/(SICI)1096-9896(199911)189:3<344::AID-PATH430>3.0.CO;2-G
19. FOLKMANN J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31. doi:10.1038/ nm0195-27
20. HUANG G, CHEN L: Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma. J Cancer Res Clin Oncol 2010; 136: 1201-1211. doi:10.1007/s00432-010-0770-6
21. KLAGSBRUN M, D'AMORE PA: Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217-239. doi:10.1146/annurev. ph.53.030191.001245
22. GALLAGHER WM, CURRIDd CA, WHELAN LC: Fibulins and cancer: friend or foe? Trends Mol Med 2005; 11: 336-340. doi:10.1016/j.molmed.2005.06.001
23. LECKA-CZERNIK B, LUMPKIN CK Jr, GOLDSTEINOLDSTEIN S: An overexpressed gene transcript in senescent and quiescent human fibroblasts encoding a novel protein in the epidermal growth factor-like repeat family stimulates DNA synthesis. Mol Cell Biol 1995; 15: 120-128.
24. STONE EM, LOTERY AJ, MUNIER FL, HEON E, PIGUET B et al.: A single EFEMP1 mutation associated with both Malattia Leventinese and Doyne honeycomb retinal dystrophy. Nat Genet 1999; 22:199-202. doi: 10.1038/9722
25. LOPEZ J, PERCHARDE M, COLEY HM, WEBBB A, CROOK. T: The context and potential of epigenetics in oncology. Br J Cancer 2009; 100:571-577. doi: 10.1038/sj.bjc.6604930
26. ZHANG YW, MIAO YF, YI J, GENG J, WANG R et al: Transcriptional inactivation of secreted frizzled-related protein 1 by promoter hypermethylation as a potential biomarker for non-small cell lung cancer. Neoplasma 2010; 57: 228-233. doi:10.4149/neo_2010_03_228
27. ZLOBEC I, LUGLI A: Prognostic and predictive factors. in colorectal cancer. Postgrad Med J 2008; 84: 403-411. doi:10.1136/jcp.2007.054858
28. CHEN L, SUN B, ZHANG S, ZHAO X, HE Y et al.: Influence of. microenvironments on microcirculation patterns and tumor invasion-related protein expression in melanoma. Oncol Rep 2009; 21: 917-923.
29. RADISKY DC, STALLINGS-MANN M, HIRAI Y, BISSEL. MJ: Single proteins might have dual but related functions in intracellular and extracellular microenvironments. Nat Rev Mol Cell Biol 2009; 10: 228-234. doi:10.1038/nrm2633
30. KLENOTIC PA, MUNIER FL, MARMORSTEIN LY, ANAND-APTE B: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a binding partner of epithelial growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1). Implications for macular degenerations. J Biol Chem 2004; 279:30469-30473. doi: 10.1074/jbc.M403026200
31. CAMAJ P, SEELIGER H, ISCHENKO I, KREBS S, BLUM H. et al.: EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem 2009; 390:1293-1302. doi: 10.1515/BC.2009.140.